Optimized CDMO
Services
Defined by a culture of collaboration and innovation, OmniaBio is a leader in cell and gene therapy (CGT) manufacturing. With deep experience in CGT and seated within a thriving CGT ecosystem, we accelerate development through:
- Access to key thought leaders and deep expertise
- Housing the latest critical manufacturing and analytical equipment specifically for CGT applications
- Delivering project-specific key milestones on time and on target
Your Idea, Our Expertise
As a focused CDMO in the cell and gene therapy space, we have extensive knowledge and expertise in the field. With our leading platforms in iPSC, lentiviral vectors and immunotherapy, we are advancing the science of cell and gene therapies and unlocking their medicinal potential.
Immunotherapy
Offering the latest technologies for development and manufacturing CAR T, NK, and beyond
Lentiviral Vectors
Enabling end-to-end support and a fully integrated platform for Lentivirus production
iPSC
More Than a Facility
An Ecosystem of CGT-Focused Capabilities
OmniaBio is the latest addition to a vibrant Canadian CGT ecosystem. Strategically placed in Ontario and established in 2022 as a subsidiary of CCRM, the focus of OmniaBio spans from preclinical, process and analytical development through manufacturing of iPSC, LVV and immuno-based therapeutics. OmniaBio benefits from CCRM’s technical and commercialization expertise, and well-established infrastructure, to propel the clinical translation and facilitate the development of next generation solutions. Together, OmniaBio and CCRM are focused on the future development and clinical success of CGT today.
